Cargando…
Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus
Pancreatic neuroendocrine neoplasms (pNENs) account for 2–3% of pancreatic malignancies. Peroxiredoxins (Prdxs), which are major cellular antioxidants, are involved in multiple oncogenic signaling pathways. We investigated the role of peroxiredoxin-2 in QGP-1 human pNEN cell line and patient-derived...
Autores principales: | Kim, Eui Joo, Kim, Yoon Jae, Lee, Hye In, Jeong, Seok-Hoo, Nam, Hyo Jung, Cho, Jae Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696978/ https://www.ncbi.nlm.nih.gov/pubmed/33182509 http://dx.doi.org/10.3390/antiox9111104 |
Ejemplares similares
-
NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression
por: Kim, Eui Joo, et al.
Publicado: (2020) -
Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012) -
High-resolution endoscopic ultrasound imaging and the number of needle passages are significant factors predicting high yield of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid masses without an on-site cytopathologist
por: Jeong, Seok Hoo, et al.
Publicado: (2017) -
Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
por: Cen, Putao, et al.
Publicado: (2012) -
Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
por: Kurita, Yusuke, et al.
Publicado: (2022)